About: Efavirenz

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efavirenz Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B5A14-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5A15-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5A16-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK: Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14410-5. Epub 2002 Oct 17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12386343 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	40-55 hours (en)
http://linked.open...ugbank/indication	For use in combination treatment of HIV infection (AIDS) (en)
http://linked.open...bank/manufacturer	Baxter healthcare corp anesthesia and critical care Bristol myers squibb pharma co
sameAs	Efavirenz
Title	Efavirenz (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/bindingdb/2483 http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/chebi/119486 http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/chemspider/57715 http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/drugbank/DB00625 http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/kegg-compound/C08088 http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/kegg-drug/D00896 http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/national-drug-code-directory/0056-0474-92 http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/pdb/EFZ http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/pharmgkb/PA449441 http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/pubchem-compound/64139 http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/pubchem-substance/46506827 http://linked.opendata.cz/resource/drugbank/drug/DB00625/identifier/wikipedia/Efavirenz
http://linked.open...mechanismOfAction	Similar to zidovudine, efavirenz inhibits the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). Antiviral activity of efavirenz is dependent on intracellular conversion to the active triphosphorylated form. The rate of efavirenz phosphorylation varies, depending on cell type. It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body. Even though human DNA polymerase is less susceptible to the pharmacologic effects of triphosphorylated efavirenz, this action may nevertheless account for some of the drug's toxicity. (en)
http://linked.open...drugbank/packager	Apotheca Inc. App pharmaceuticals llc Amerisource Health Services Corp. A-S Medication Solutions LLC Abraxis pharmaceutical products
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/2101572 http://linked.opendata.cz/resource/drugbank/patent/2279198 http://linked.opendata.cz/resource/drugbank/patent/5811423 http://linked.opendata.cz/resource/drugbank/patent/6238695
http://linked.open...outeOfElimination	Nearly all of the urinary excretion of the radiolabeled drug was in the form of metabolites. (en)
http://linked.open.../drugbank/synonym	Efavirenz (en) (S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one (en) Efavirenzum (en) (-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (en) 6-chloro-4-(2-Cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one (en) Éfavirenz (en) (S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/08-18-08-16
http://linked.open...k/foodInteraction	Avoid excessive or chronic alcohol consumption. (en) Take without regard to meals. (en)
http://linked.open...nk/proteinBinding	99.5-99.75% (en)
http://linked.open...ynthesisReference	John Doney, "Amorphous efavirenz and the production thereof." U.S. Patent US20070026073, issued February 01, 2007. (en)
foaf:page	http://www.drugs.com/cdi/efavirenz.html http://www.rxlist.com/cgi/generic/efaviren.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5A1B-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B5A21-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5A20-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5A1D-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5A1E-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B5A1F-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B5A19-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B5A17-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5A1A-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5A32-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B5A18-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Efavirenz
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5A27-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5A28-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B5A22-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B5A23-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B5A25-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B5A24-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B5A26-363D-11E5-9242-09173F13E4C5
http://linked.open.../affectedOrganism	Human Immunodeficiency Virus (en)
http://linked.open...casRegistryNumber	154598-52-4 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...gbank/containedIn	Apo-Nitrazepam 10 mg Tablet Cafergot 1-100 mg tablet Darvon-n 100 mg tablet Esgic-plus 50-500-40 mg tablet
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B5A2D-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B5A2F-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B5A30-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B5A31-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B5A2C-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B5A2B-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B5A2E-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5A1C-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B5A29-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B5A2A-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software